Publicaciones en las que colabora con José Ramón Blanco Ramos (24)

2022

  1. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. La investigación frente al SARS-COV-2 y la COVID-19 en el Departamento de Enfermedades Infecciosas del Hospital Universitario San Pedro-CIBIR

    Zubía, Núm. 39, pp. 63-73

  2. Maraviroc prevents hcc development by suppressing macrophages and the liver progenitor cell response in a murine chronic liver disease model

    Cancers, Vol. 13, Núm. 19

  3. Mural Endocarditis: The GAMES Registry Series and Review of the Literature

    Infectious Diseases and Therapy, Vol. 10, Núm. 4, pp. 2749-2764

2019

  1. Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry

    General Thoracic and Cardiovascular Surgery, Vol. 67, Núm. 7, pp. 585-593

  2. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71

2018

  1. Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis

    Journal of Infection and Chemotherapy, Vol. 24, Núm. 7, pp. 555-562

  2. Infective Endocarditis in Patients With Bicuspid Aortic Valve or Mitral Valve Prolapse

    Journal of the American College of Cardiology, Vol. 71, Núm. 24, pp. 2731-2740

  3. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet

    Translational Research, Vol. 196, pp. 17-30

2017

  1. Maraviroc ameliorates the increased adipose tissue macrophage recruitment induced by a high-fat diet in a mouse model of obesity

    Antiviral Therapy, Vol. 22, Núm. 2, pp. 163-168

2016

  1. High prevalence of asymptomatic carriers of Tropheryma whipplei in different populations from the North of Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 34, Núm. 6, pp. 340-345

  2. Off-label use of maraviroc in clinical practice

    Expert Review of Anti-Infective Therapy

2015

  1. Maraviroc modifica la composición de la microbiota intestinal en un modelo animal de obesidad: Una posible opción terapéutica para prevenir los trastornos metabólicos en pacientes infectados por el VIH

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 4, pp. 200-206

  2. Shorter telomere length predicts poorer immunological recovery in virologically suppressed hiv-1-infected patients treated with combined antiretroviral therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 68, Núm. 1, pp. 21-29

2014

  1. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 7, pp. 1903-1910

2013

  1. Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model

    PLoS ONE, Vol. 8, Núm. 1

  2. Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: A pilot study

    Journal of the International AIDS Society, Vol. 16

  3. Role of mitochondria in HIV infection and associated metabolic disorders: Focus on nonalcoholic fatty liver disease and lipodystrophy syndrome

    Oxidative Medicine and Cellular Longevity

2012

  1. 1987, un caso de enfermedad de lyme - 2012: Centro de Referencia de Rickettsiosis y Enfermedades Transmitidas por Artrópodos Vectores

    Zubía, Núm. 24, pp. 149

  2. Could CCR5 be a potential target against infections?

    Expert Review of Anti-Infective Therapy